Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

VRÁBEL Dávid GREGOROVÁ Jana SEDLAŘÍKOVÁ Lenka ALMÁŠI Martina BEZDĚKOVÁ Renata ŠTORK Martin KREJČÍ Marta ADAM Zdeněk POUR Luděk HAJEK Roman ŠEVČÍKOVÁ Sabina

Year of publication 2018
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous cancer of plasma cells characterized by multiple focal lesions in the bone marrow (BM). Hence, a single-site biopsy can create a sampling bias. In spite of this, BM samples are typically used for MRD analysis, but currently an alternative approach called liquid biopsies, which utilizes body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA (cfDNA) as one type of the molecule which can be analyzed using liquid biopsy approach showed promising results previously. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in bone marrow samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.